ArticleInvestigational new drugs2018

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Glen J Weiss et al.PubMed ↗Publisher ↗

No numbers read from the abstract.